Economic impact of heart failure with preserved ejection fraction: insights from the ALDO‐DHF trial
Abstract Aims Although heart failure (HF) with preserved ejection fraction (HFpEF) is a leading cause for hospitalization, its overall costs remain unclear. Therefore, we assessed the health care‐related costs of ambulatory HFpEF patients and the effect of spironolactone. Methods and results The ald...
Saved in:
Main Authors: | Djawid Hashemi, Ludwig Dettmann, Tobias D. Trippel, Volker Holzendorf, Johannes Petutschnigg, Rolf Wachter, Gerd Hasenfuß, Burkert Pieske, Antonia Zapf, Frank Edelmann |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-06-01
|
Series: | ESC Heart Failure |
Subjects: | |
Online Access: | https://doi.org/10.1002/ehf2.12606 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Syncopes and clinical outcome in heart failure: results from prospective clinical study data in Germany
by: Djawid Hashemi, et al.
Published: (2020-06-01) -
Heart failure with mildly reduced ejection fraction: retrospective study of ejection fraction trajectory risk
by: Robert J.H. Miller, et al.
Published: (2022-06-01) -
Rehospitalization burden and morbidity risk in patients with heart failure with mid‐range ejection fraction
by: Enrique Santas, et al.
Published: (2020-06-01) -
Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trial
by: Rolf Wachter, et al.
Published: (2020-06-01) -
The heart failure specialists of tomorrow: a network for young cardiovascular scientists and clinicians
by: Markus S. Anker, et al.
Published: (2020-06-01)